

Preparation of Recombinant Bone Morphogenetic Protein 2 at Laboratory Scale

Mahmoud Kazemi^a, Ali Hassani^{a*}, Mojgan Bandehpour^{b,c}, Leila Bahrami^d, Bahram Kazemi^{b,c*}

^a Islamic Azad University, Dental Branch of Tehran, Tehran, Iran; ^b Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^c School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^d School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Bahram Kazemi, Shahid Beheshti University of Medical Sciences, Tehran, Iran. E-mail: kazemi@sbmu.ac.ir; Tel: +98-912 326835 and Ali Hassani, Dental Branch of Tehran, Azad University, Tehran, Iran; Email: drhassani.omfs@gmail.com, Tel: +98-21 88792122

Submitted: 2016-02-15; Accepted: 2016-04-28

Introduction: Millions cases of bone fracture are reported annually worldwide. The conventional methods for the repair often fail. The complications of using routine methods include stimulation of bone repair which should be performed without infection risk and immunologic responses. The aim of this study was cloning and expression of bone morphogenetic protein 2 (BMP2), a key growth factor used in bone repair. **Materials and Methods:** mRNA was extracted from human maxillary osteosarcoma and reverse transcribed. The BMP2 gene was amplified by PCR and cloned into pETDuet vector and was expressed. **Results:** The BMP2 gene was expressed successfully and expression was confirmed by western blotting using anti- His tag antibody. **Conclusion:** Recombinant protein preparation method has been recognized to be accessible and the production is cost effective.

Keywords: BMP2; Bone regeneration; Bone fracture

Introduction

Millions cases of bone fracture are reported annually in the world. The conventional methods for repair often fail which cause cost burden and stress for the society (1-3). By the improvement in the surgical techniques, fixation, and biological sciences, healing of some fractures are delayed; nonetheless, in 4% of the cases relapse occurs after treatment. There is an increase in the usage of fast dental implant for quicker recovery and prevention of alveolar bone atrophy; however, if there is no similarity between implant shape and socket, the implant could be failed (4). These cause challenges for reconstructive surgeons due to the fracture repair complexity which leads to dysfunction movement and chronic mental state in patients (5).

Conventional treatments for bone repair include using autograft, allograft, and xenograft materials. The complications of using these routine methods are stimulation of bone repair with infection risk and immunologic responses. Moreover, the problems with application of autograft includes the need for appropriate selection of recipient and donor sites, and morbidity in donor site (5).

Application of appropriate growth factors for fast bone regeneration could be an alternative solution to overcome those

obstacles (6, 7). Bone morphogenetic proteins 2 (BMP2) is a growth factor which is produced in human organs with a significant role in bone repair process. BMP2 extraction from human body is quite a problematic method and has not been identified as a desirable method for patients; in addition, it is costly. However, mass production of recombinant BMP2 is accessible and comfortable for patients (8, 9). The aim of the present study was cloning and expression of BMP2 and preparation for mass production to be used for future studies.

Materials and Methods

Gene cloning

mRNA was extracted from human maxillary osteosarcoma by RNA extraction kit (Fermentas, Waltham, Massachusetts, USA, 02451) and reverse transcribed using oligo DT. BMP2 gene was amplified by specific primers based on Accession NO M22489. PCR product was detected on 1.5% agarose gel electrophoresis and cloned into pBluescript plasmid via T/A cloning method. Ligation reaction was transformed into DH5α competent cell and spread on agar plate containing 100μg/ML ampicillin and X-gal and IPTG. White bacterial colonies containing recombinant plasmid were selected.




Figure 1. Bacterial plate containing white and blue colonies




Figure 2. 0.8% agarose gel electrophoresis for digested and undigested plasmid. Lane 1 and 3 present undigested plasmids. Lane 2 and 4 present BamHI and EcoRI digested plasmid. Released BMP2 gene is shown.

Gene expression

Plasmid was extracted using alkaline lysis method (10) and it was digested by BamHI and EcoRI restriction enzymes. The released fragment (BMP2 gene) was purified, and sub-cloned into enzyme digested expression pETDuet vector. Recombinant expression plasmid was transformed into BL21 (DE3) *E. coli* strain. Recombinant BMP2 plasmid was extracted and the results were confirmed by PCR.

E. coli which contained recombinant plasmid was cultured into YT medium (11) and incubated overnight; consequently, plasmid promoter was induced by 0.5 mM IPTG (12). Sampling was performed before induction for 4 times by one-hour interval after induction. Bacterial samples were lysed and electrophoresed on 12% SDS-PAGE along with protein marker and *E. coli* without plasmid. Expressed protein was transferred into nitrocellulose membrane and detected by anti His Tag antibody and Horse Radish Peroxidase (western blotting) (13).




Figure 3. 2% gel electrophoresis of recombinant plasmid PCR product. Lane 1, DNA size marker. Lane 2 and 3 present PCR product for recombinant plasmid. Lane 4, PCR reaction of empty plasmid




Figure 4. SDS-PAGE of recombinant plasmid. Lane 1, protein marker. Lane 2, bacterial lysate containing recombinant plasmid expressed approximately 42 KDa protein. Lane 3 bacterial lysate containing empty plasmid

Results

mRNA was extracted from human maxillary osteosarcoma and reverse transcribed by oligo dT. Then, BMP2 gene was amplified by specific primers and PCR product (BMP2 gene) was gel electrophoresed and cloned via T/A cloning method. Plasmid screening was performed by X-gal-IPTG and white colonies (Figure 1) containing recombinant plasmid were cultured; eventually, plasmid extraction was attained.

Recombinant plasmid was digested using BamHI and EcoRI restriction enzymes, then, it gel electrophoresed (Figure 2). Released fragment (BMP2 gene) was purified and sub-cloned into expression pETDuet plasmid.

Sampling was performed before and after induction, then, it lysed, and electrophoresed. Figure 4 shows commassie brilliant blue stained expressed approximately 42 KDa protein on SDS-PAGE. Figure 5 shows detected protein by anti-His tag antibody and Horse Radish peroxidase by western blot




Figure 5. Western blot detected by anti His tag antibody. Lane 1, protein marker. Lane 2, bacterial lysate containing recombinant plasmid. Lane 3 bacterial lysate containing empty plasmid

Discussion

Bone morphogenetic proteins 2 (BMP2) is a growth factor produced in human organs which plays a significant role in bone repair. BMP2 has been used in bone regeneration as well (14). BMP2 protein has been demonstrated to be a stimulator for bone generation in fracture repair such as non-union fracture (15, 16).

Xiong *et al.* prepared rhBMP2 in *E. coli* and purified protein implanted into mesenchymal cells; in addition, they showed new cartilage and bone formation (17). Ma *et al.* expressed rhBMP2 in *E. coli* and proposed that rhBMP2 has biological capacity for ectopic bone formation (18). Ihm *et al.* expressed hBMP2 in soluble form in *E. coli* (19).

Conclusion

Extraction and purification of BMP2 growth factor from human blood is a complex method and its production has low efficiency, however, preparation by recombination is an easy method to be used. Human product cannot be stored for long time and has a high possibility of infection by viruses. Recombinant protein preparation method has been recognized to be accessible and the production is cost effective.

Acknowledgement

This paper was extracted from Mahmoud Kazemi DD doctorate thesis and supported by Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Conflict of Interest: 'None declared'.

References

1. Pressley JC, Kendig TD, Frencher SK, Barlow B, Quitel L, Waqar F. Epidemiology of bone fracture across the age span in blacks and whites. *J Trauma*. 2011;71(5 Suppl 2):S541-8.

2. Dhanwal DK, Dennison EM, Harvey NC, Cooper C. Epidemiology of hip fracture: Worldwide geographic variation. *Indian J Orthop*. 2011;45(1):15-22.
3. Filipov O. Epidemiology and social burden of the femoral neck fractures. *Journal of IMAB-Annual Proceeding Scientific Papers*. 2014;20(4):516-8.
4. Allareddy V, Allareddy V, Nalliah RP. Epidemiology of facial fracture injuries. *J Oral Maxillofac Surg*. 2011;69(10):2613-8.
5. Chee W, Jivraj S. Failures in implant dentistry. *Br Dent J*. 2007;202(3):123-9.
6. Park J, Ries J, Gelse K, Kloss F, von der Mark K, Wiltfang J, et al. Bone regeneration in critical size defects by cell-mediated BMP-2 gene transfer: a comparison of adenoviral vectors and liposomes. *Gene Ther*. 2003;10(13):1089-98.
7. Rao SM, Ugale GM, Warad SB. Bone morphogenetic proteins: periodontal regeneration. *N Am J Med Sci*. 2013;5(3):161-8.
8. Erickson DM, Harris SE, Dean DD, Harris MA, Wozney JM, Boyan BD, et al. Recombinant bone morphogenetic protein (BMP)-2 regulates costochondral growth plate chondrocytes and induces expression of BMP-2 and BMP-4 in a cell maturation-dependent manner. *J Orthop Res*. 1997;15(3):371-80.
9. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. *Spine J*. 2011;11(6):471-91.
10. Clemson M, Kelly WJ. Optimizing alkaline lysis for DNA plasmid recovery. *Biotechnol Appl Biochem*. 2003;37(Pt 3):235-44.
11. Kram KE, Finkel SE. Rich Medium Composition Affects *Escherichia coli* Survival, Glycation, and Mutation Frequency during Long-Term Batch Culture. *Appl Environ Microbiol*. 2015;81(13):4442-50.
12. Hansen LH, Knudsen S, Sorensen SJ. The effect of the lacY gene on the induction of IPTG inducible promoters, studied in *Escherichia coli* and *Pseudomonas fluorescens*. *Curr Microbiol*. 1998;36(6):341-7.
13. Burnette WN. Western blotting: remembrance of things past. *Methods Mol Biol*. 2015;1312:9-12.
14. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. *Growth Factors*. 2004;22(4):233-41.
15. Carreira AC, Zambuzzi WF, Rossi MC, Astorino Filho R, Sogayar MC, Granjeiro JM. Bone Morphogenetic Proteins: Promising Molecules for Bone Healing, Bioengineering, and Regenerative Medicine. *Vitam Horm*. 2015;99:293-322.
16. Khan SN, Lane JM. The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications. *Expert Opin Biol Ther*. 2004;4(5):741-8.
17. Xiong S, Yu L, Tan H, Huang T, Wang C, Liu D, et al. Expression and purification of recombinant bone morphogenetic protein-2 in *E. coli*. *Di 1 jun yi da xue xue bao= Academic journal of the first medical college of PLA*. 2002;22(5):413-6.
18. Ma Q, Dang G, Ma D. Human bone morphogenetic protein-2: recombinant expression in *E. coli*. *Zhonghua Yi Xue Za Zhi*. 1998;78(4):308-10.
19. Ihm HJ, Yang SJ, Huh JW, Choi SY, Cho SW. Soluble expression and purification of synthetic human bone morphogenetic protein-2 in *Escherichia coli*. *BMB Rep*. 2008;41(5):404-7.

Please cite this paper as: Kazemi M, Hassani A, Bandehpour M, Bahrami L, Kazemi B. Preparation of Recombinant Bone Morphogenetic Protein at Laboratory Scale. *Regen Reconstr Restor*. 2016; 1(3):121-123.

